Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaglenastat + Palbociclib in Advanced Solid Tumors
NCT03965845Phase 2Completed
- Sponsor
- Calithera Biosciences
- Start
- Jun 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of telaglenastat in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), sponsored by Calithera Biosciences. Started Jun 2019; status: completed.
02
Drugs
telaglenastat
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03965845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965845.